Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome Market

Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by an increase in the triglycerides (TGs) level due to a reduction in the LPL, which is an enzyme that helps to break down chylomicrons (CMs) in the body. The reduction in the LPL leads to the buildup of CMs, which are rich in triglycerides. 


The normal TGs levels are <150 mg/dL (or 1.7 mmol/L), but in FCS, the TGs level increases about 10 to 20 times from the normal level. It is also known as lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, endogenous hypertriglyceridemia, familial fat-induced hypertriglyceridemia, familial hyperchylomicronemia, and familial LPL deficiency, hyperlipidemia Type I (fredrickson), hyperlipoproteinemia Type IA, lipase D deficiency, and Burger-Grutz syndrome. 


Familial Chylomicronemia Syndrome Epidemiological Segmentation 

The Epidemiological Segmentation of Familial Chylomicronemia Syndrome in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalence of FCS 
  • Total Diagnosed Prevalence of FCS
  • Age-specific Diagnosed Prevalence of FCS
  • Severity- Specific Diagnosed Prevalence of FCS
  • Treated Patient Pool of FCS 


Familial Chylomicronemia Syndrome Epidemiology 

  • The total prevalent population of FCS in the 7MM in 2017 was 5,801 
  • 73% of FCS cases belong to age-group 0–10 years in the 7MM in 2017 


Familial Chylomicronemia Syndrome Market

The market size of FCS in the 7MM in 2017 was USD 1.0 million  


Familial Chylomicronemia Syndrome Market Drivers

  • Rise of the Oligonucleotides in the Treatment of FCS
  • Increase in the Prevalence Rate of FCS 
  • Non-adherence to Extremely Restrictive Low-fat Diet
  • Improvement in the Diagnosis

 

Familial Chylomicronemia Syndrome Market Barriers

  • Challenges in the Clinical Trials for Therapies
  • Delayed Diagnosis of FCS
  • Barriers in the Access or Reimbursement of Therapies
  • Burden of Disease


Familial Chylomicronemia Syndrome Emerging Drugs

The emerging drugs of the Familial Chylomicronemia Syndrome market are 

  • AKCEA-ANGPTL3-LRx
  • ARO-APOC3
  • Lomitapide
  • AKCEA -APOCIII - LRx

And many others. 


Familial Chylomicronemia Syndrome Key Players

The key players in the Familial Chylomicronemia Syndrome market are

  • Akcea Therapeutics
  • Ionis Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Amryt Pharma
  • Novelion Therapeutics

And many others.